Insmed
INSMInsmed is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases across three core therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Insmed is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases across three core therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The company's value proposition centers on its proprietary drug delivery technologies, such as Pulmovance liposomal delivery, and its ability to advance first-in-class treatments for chronic lung infections and inflammatory conditions.
Insmed holds a leading position in the NTM lung disease market with the only approved inhaled therapy in major regions and is a first-mover in the bronchiectasis space with the recent approval of BRINSUPRI.
Questions, answered.
- What is Insmed's market cap?
- Insmed (INSM) has a market capitalization of $25.3B and trades on NASDAQ.
- What is Insmed's revenue and profitability?
- Insmed generated $819.6M in trailing twelve-month revenue with a net loss of $1.2B, representing a net margin of -144.4%. Gross margin stands at 81.8%, with free cash flow of -$921.6M. These figures are based on the Q1 2026 filing.
- Who are Insmed's competitors?
- Insmed's key competitors include United Therapeutics Corporation, Sarepta Therapeutics, Inc., Spero Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Insmed partner with?
- Insmed's notable partners include AstraZeneca, PARI Pharma GmbH, Thermo Fisher Scientific, Inc., and others.
- Where is Insmed headquartered?
- Insmed is headquartered in United States of America and employs approximately 912 people. It has been publicly traded since 2000.
